Management recently flagged licence and UK order book development below levels anticipated at the AGM and lowered FY19 PBT guidance to the £9.5–10m range. The share price is now at its lowest level for over five years and – trading below NAV – implicitly attributes no value to the brand portfolio. A dividend yield in excess of 5% could also be an attraction.
Written by
Walker Greenbank |
Earnings pressure but asset backing |
H118 update |
Care & household goods |
3 August 2018 |
Share price performance
Business description
Next events
Analyst
Walker Greenbank is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
Management recently flagged licence and UK order book development below levels anticipated at the AGM and lowered FY19 PBT guidance to the £9.5–10m range. The share price is now at its lowest level for over five years and – trading below NAV – implicitly attributes no value to the brand portfolio. A dividend yield in excess of 5% could also be an attraction.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
01/17 |
92.4 |
10.4 |
12.9 |
3.6 |
6.0 |
4.7 |
01/18 |
108.8 |
12.5 |
14.4 |
4.4 |
5.4 |
5.6 |
01/19e |
106.0 |
9.5 |
10.8 |
4.4 |
7.2 |
5.6 |
01/20e |
107.9 |
9.6 |
10.9 |
4.4 |
7.1 |
5.6 |
Note: *PBT and EPS (fully diluted) are normalised, excluding exceptional items and LTIP charges.
Recent trading newsflow disappoints
Disappointing sales development in the last month prompted a weak trading update (24 July). Licence income has grown in recent years (to £3.1m in FY18) and the largest single agreement to date was signed in H1, all to be booked in FY19. However, earlier expectations were for it to have been higher value; any shortfall in this revenue stream has a disproportionate impact on profit. Secondly, UK Brand order intake has disappointed in recent weeks (H119 revenue -6.8% overall). John Lewis Partnership’s weekly sales development corroborates this; year-to-date Home category sales development has gone from -2.7% (and stable) just before Walker Greenbank’s AGM to -4.0% four trading weeks later, with more variable negative weekly figures. More positively, US Brand sales (+4.9% l-f-l), Licensing (+40.4%) and third-party Manufacturing (+11.1%) have all shown good y-o-y progress ytd.
Estimate revisions focused on the UK
Retailers generally have pointed to better outdoor category sales in the UK and it remains to be seen whether the consumer has been distracted temporarily (by the hot weather / World Cup / Brexit newsflow) or whether the current activity levels are to be sustained. Taking management’s FY19 PBT guidance, we have lowered our current year estimate by 26%, substantially driven by Brands. Moreover, we now assume no UK Brand growth from a reduced FY19 base level in FY20 and FY21, and this feeds through to similar PBT reductions in these two years also, pending more positive consumer confidence readings.
Valuation: Low rating in context
The company’s share price gapped down following the 24 July update and is at levels last seen in early 2013 during the post-recession recovery phase. Increased confidence in the earnings outlook would naturally result in some expansion of valuation multiples from current levels (FY19 P/E 7.2x, EV/EBITDA, adjusted for pensions cash 4.6x), in our view. In the light of our estimate revisions, we have elected to factor in a flat DPS profile (previously a 5.5% CAGR); on this basis earnings cover remains comfortably above 2x and the balance sheet to us seems strong. Indeed, the share price now sits below our projected 90p end-FY19 NAV.
Exhibit 1: Financial summary
£m |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019e |
2020e |
2021e |
||
January |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
|
75.7 |
78.4 |
83.4 |
87.8 |
92.4 |
108.8 |
106.0 |
107.9 |
111.0 |
Cost of Sales |
|
|
(30.2) |
(30.3) |
(32.7) |
(35.9) |
(36.2) |
(43.3) |
(41.8) |
(42.5) |
(43.7) |
Gross Profit |
|
|
45.5 |
48.1 |
50.7 |
52.0 |
56.2 |
65.5 |
64.2 |
65.4 |
67.3 |
EBITDA |
|
|
8.6 |
9.7 |
10.7 |
11.8 |
13.4 |
15.9 |
13.0 |
13.3 |
14.1 |
Operating Profit (before GW, except. & LTIP) |
6.6 |
7.5 |
8.3 |
9.1 |
10.6 |
12.8 |
9.9 |
10.0 |
10.7 |
||
Operating Profit (before GW and except.) - reported |
5.8 |
6.5 |
7.3 |
8.2 |
9.8 |
12.4 |
9.3 |
9.4 |
10.1 |
||
Net Interest |
|
|
(0.2) |
(0.2) |
(0.2) |
(0.2) |
(0.2) |
(0.3) |
(0.4) |
(0.3) |
(0.3) |
Intangible Amortisation - acquired |
|
|
0 |
0 |
0 |
0 |
(0.3) |
(1.0) |
(1.0) |
(1.0) |
(1.0) |
Pension net finance charge |
(0.7) |
(0.9) |
(0.8) |
(0.7) |
(0.5) |
(0.6) |
(0.6) |
(0.6) |
(0.6) |
||
Exceptionals |
|
|
0 |
0 |
0 |
0 |
(1.8) |
2.3 |
0.0 |
0.0 |
0.0 |
Other |
|
|
0 |
0 |
0 |
0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Profit Before Tax (norm) |
|
|
6.4 |
7.3 |
8.1 |
8.9 |
10.4 |
12.5 |
9.5 |
9.6 |
10.4 |
Profit Before Tax (FRS 3) |
|
|
4.9 |
5.5 |
6.3 |
7.3 |
7.0 |
12.8 |
7.3 |
7.4 |
8.2 |
Tax |
|
|
(1.0) |
(0.5) |
(1.2) |
(1.5) |
(1.6) |
(1.0) |
(1.9) |
(1.9) |
(2.1) |
Profit After Tax (norm) |
|
|
5.4 |
6.6 |
6.9 |
7.5 |
8.6 |
11.5 |
7.6 |
7.7 |
8.3 |
Profit After Tax (FRS 3) |
|
|
4.0 |
5.0 |
5.1 |
5.9 |
5.4 |
11.8 |
5.4 |
5.5 |
6.1 |
|
|
|
|
|
|
|
|
|
|
|
|
Average Number of Shares Outstanding (m) |
|
57.5 |
58.5 |
59.3 |
60.0 |
62.7 |
70.4 |
70.7 |
70.7 |
70.7 |
|
EPS - normalised (p) FD |
|
|
9.4 |
10.7 |
11.2 |
11.6 |
12.9 |
14.4 |
10.8 |
10.9 |
11.8 |
EPS - FRS 3 (p) |
|
|
6.9 |
8.6 |
8.6 |
9.8 |
8.6 |
16.7 |
7.7 |
7.8 |
8.7 |
Dividend per share (p) |
|
|
1.5 |
1.9 |
2.3 |
2.9 |
3.6 |
4.4 |
4.4 |
4.4 |
4.4 |
|
|
|
|
|
|
|
|
|
|
|
|
Gross Margin (%) |
|
|
60.1 |
61.3 |
60.8 |
59.2 |
60.8 |
60.2 |
60.6 |
60.6 |
60.6 |
EBITDA Margin (%) |
|
|
11.4 |
12.4 |
12.8 |
13.4 |
14.6 |
14.6 |
12.3 |
12.3 |
12.7 |
Operating Margin (before GW and except.) (%) |
7.7 |
8.3 |
8.8 |
9.3 |
10.7 |
11.4 |
8.7 |
8.7 |
9.1 |
||
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE SHEET |
|
|
|
|
|
|
|
|
|
|
|
Fixed Assets |
|
|
18.5 |
21.1 |
21.5 |
18.9 |
47.5 |
47.7 |
47.6 |
46.8 |
45.9 |
Intangible Assets |
|
|
6.7 |
7.3 |
7.2 |
7.1 |
31.6 |
31.8 |
30.6 |
29.5 |
28.4 |
Tangible Assets |
|
|
9.8 |
11.7 |
12.7 |
11.7 |
15.8 |
16.0 |
16.9 |
17.3 |
17.5 |
Investments |
|
|
2.0 |
2.2 |
1.6 |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Current Assets |
|
|
32.6 |
35.3 |
37.1 |
40.3 |
51.3 |
51.9 |
53.1 |
54.8 |
57.4 |
Stocks |
|
|
16.8 |
18.4 |
22.0 |
18.1 |
30.3 |
29.4 |
30.4 |
30.9 |
31.8 |
Debtors |
|
|
12.8 |
13.9 |
14.1 |
19.3 |
19.5 |
21.2 |
21.4 |
21.6 |
22.1 |
Cash |
|
|
2.9 |
2.8 |
1.0 |
2.9 |
1.5 |
1.3 |
1.3 |
2.3 |
3.5 |
Other |
|
|
0.1 |
0.2 |
0.0 |
0.0 |
|
|
|
|
|
Current Liabilities |
|
|
(17.3) |
(19.4) |
(20.7) |
(19.4) |
(34.8) |
(28.9) |
(29.6) |
(30.2) |
(31.1) |
Creditors |
|
|
(16.9) |
(19.0) |
(20.3) |
(19.0) |
(28.0) |
(22.4) |
(23.0) |
(23.6) |
(24.5) |
Short term borrowings |
|
|
(0.4) |
(0.4) |
(0.4) |
(0.4) |
(6.8) |
(6.6) |
(6.6) |
(6.6) |
(6.6) |
Long Term Liabilities |
|
|
(9.6) |
(10.2) |
(10.9) |
(4.5) |
(12.7) |
(9.1) |
(7.1) |
(5.0) |
(2.8) |
Long term borrowings |
|
|
(1.4) |
(0.9) |
(0.6) |
(0.2) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Other long term liabilities |
|
|
(8.2) |
(9.2) |
(10.4) |
(4.3) |
(12.7) |
(9.1) |
(7.1) |
(5.0) |
(2.8) |
Net Assets |
|
|
24.2 |
26.9 |
26.9 |
35.3 |
51.3 |
61.6 |
63.9 |
66.3 |
69.4 |
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOW |
|
|
|
|
|
|
|
|
|
|
|
Operating Cash Flow |
|
|
6.0 |
6.2 |
3.5 |
7.1 |
12.4 |
7.0 |
9.3 |
9.8 |
10.2 |
Net Interest |
|
|
(0.2) |
(0.2) |
(0.2) |
(0.1) |
(0.2) |
(0.2) |
(0.3) |
(0.3) |
(0.3) |
Tax |
|
|
(0.0) |
(0.0) |
(0.0) |
(0.6) |
(2.3) |
(2.2) |
(1.9) |
(1.9) |
(2.1) |
Capex |
|
|
(3.1) |
(4.7) |
(3.2) |
(2.5) |
(6.7) |
(3.5) |
(4.0) |
(3.5) |
(3.5) |
Acquisitions/disposals |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
(27.1) |
0.0 |
0.0 |
0.0 |
0.0 |
Financing |
|
|
(0.1) |
(0.0) |
(0.4) |
(0.1) |
18.3 |
1.8 |
0.0 |
0.0 |
0.0 |
Dividends |
|
|
(0.7) |
(0.9) |
(1.1) |
(1.4) |
(1.8) |
(2.7) |
(3.1) |
(3.1) |
(3.1) |
Net Cash Flow |
|
|
1.8 |
0.3 |
(1.5) |
2.3 |
(7.4) |
0.1 |
(0.0) |
1.0 |
1.2 |
Opening net debt/(cash) |
|
|
0.7 |
(1.2) |
(1.5) |
(0.0) |
(2.3) |
5.3 |
5.3 |
5.3 |
4.3 |
HP finance leases initiated |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
(0.0) |
0.0 |
0.0 |
0.0 |
0.0 |
Other |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
(0.2) |
(0.1) |
0.0 |
0.0 |
0.0 |
Closing net debt/(cash) |
|
|
(1.2) |
(1.5) |
(0.0) |
(2.3) |
5.3 |
5.3 |
5.3 |
4.3 |
3.1 |
Source: Company, Edison Investment Research
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US |
Sydney +61 (0)2 8249 8342 Level 12, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US |
Sydney +61 (0)2 8249 8342 Level 12, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia |
During its Q218 results presentation, Bonesupport provided an update on its US commercial platform. It is working to secure distributor contracts so that sales can commence as soon as Zimmer’s exclusivity period ends on 20 October 2018. In Europe, (where all three products are marketed) trauma surgeons are showing strong interest in CERAMENT G and V. Positive outcomes from the CERTiFy (CERAMENT BVF) and FORTIFY (CERAMENT with antibiotics) studies should drive adoption in this large market. In the meantime, Bonesupport is increasing sales efforts in Europe. Our valuation is SEK1.16bn or SEK22.8/share (vs SEK22.2/share).